A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non–small cell lung cancer
Combination of GT103 with pembrolizumab was well tolerated with no new safety signals. A subset of patients experienced durable responses and disease control despite prior exposure to ICI.
Authors
- James E. Herndon (ORCID: https://orcid.org/0000-0001-7998-3588)
- Thomas E. Stinchcombe (ORCID: https://orcid.org/0000-0002-3595-8011)
- Lin Gu (ORCID: https://orcid.org/0000-0002-7504-031X)
- Ryan D. Gentzler (ORCID: https://orcid.org/0000-0002-8983-6677)
- Hirva Mamdani (ORCID: https://orcid.org/0000-0003-3874-8703)
- Edward F. Patz (ORCID: https://orcid.org/0000-0003-3374-1596)
- Sarada Gurubhagavatula
- Jeffrey Clarke (ORCID: https://orcid.org/0000-0001-5647-0245)
- Greg Andrew Durm (ORCID: https://orcid.org/0000-0003-2606-745X)
- Alberto Chiappori (ORCID: https://orcid.org/0000-0003-0810-7104)
- Frank Weinberg (ORCID: https://orcid.org/0000-0002-0094-3725)
Institutions
- Indiana University Health (US)
- Moffitt Cancer Center (US)
- University of Illinois Chicago (US)
- The Barbara Ann Karmanos Cancer Institute (US)
- Duke Institute for Health Innovation (US)
- Utility Development (United States) (US)
- United Therapeutics (United States) (US)
- G1 Therapeutics (United States) (US)
- Duke University Health System (US)
- University of Virginia (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1002/cncr.70141
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00